Peptide Initiative

Peptides · Peptide comparison

Dihexa vs Noopept (Omberacetam)

Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency

Ultra-potent dipeptide nootropic and prodrug of cycloprolylglycine that enhances cognition through BDNF/NGF upregulation, AMPA receptor modulation, and multicomponent neuroprotection at doses 1000 times lower than piracetam

  • Cognitive
  • Cognitive

At a glance

Quick comparison

Dose rangeDihexa8–20 mgNoopept (Omberacetam)10–10 mg
FrequencyDihexaOnce dailyNoopept (Omberacetam)Multiple times daily
AdministrationDihexaOral (capsule/tablet)Noopept (Omberacetam)Oral (tablet/capsule)
Cycle lengthDihexa4-6 weeksNoopept (Omberacetam)12+ weeks
Onset speedDihexaModerate (1-2 weeks)Noopept (Omberacetam)Rapid (hours to days)
Evidence levelDihexaPreclinical only — animal and cell-culture studies; no human trialsNoopept (Omberacetam)Limited human trials

Efficacy

Benefit ratings

Cognitive

Dihexa95%
Noopept (Omberacetam)No recorded rating

Healing & Recovery

Dihexa60%
Noopept (Omberacetam)No recorded rating

Anti-Aging

Dihexa55%
Noopept (Omberacetam)No recorded rating

Memory & Learning

DihexaNo recorded rating
Noopept (Omberacetam)94%

Brain Protection

DihexaNo recorded rating
Noopept (Omberacetam)91%

Mental Clarity

DihexaNo recorded rating
Noopept (Omberacetam)86%

Technical data

Compound specifications

Dihexa

Molecular formula
C27H44N4O5
Molecular weight
504.7 g/mol
Half-life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS number
1401708-83-5

Noopept (Omberacetam)

Molecular formula
C17H22N2O4
Molecular weight
318.4 g/mol
Half-life
Short plasma half-life (minutes); rapidly converted to active metabolite cycloprolylglycine which has a longer pharmacological duration; effects persist for hours after dosing
Bioavailability
Orally bioavailable with BBB penetration; metabolized to active cycloprolylglycine; approximately 1000-fold more potent than parent compound piracetam
CAS number
157115-85-0

Protocols

Dosing compared

Dihexa

Oral

  • 5–8 mgOnce daily · 2–4 weeksLower starting amount reported in practice. Dihexa has no human clinical trials, so all amounts come from animal research and community use [2][4].
  • 8–20 mgOnce daily · 4–6 weeksCommonly reported daily range in practice for cognitive support [2][4].
  • 20–45 mgOnce daily · 4–6 weeks, then reassessUpper end of amounts reported in practice. No long-term human safety data exists, so this should be approached with caution [2][4].

Sublingual

  • 5–15 mgOnce daily · 4–6 weeksHeld under the tongue as an alternative to swallowing; amounts reported in practice are similar to oral use [4].

Topical

  • 5–15 mg in DMSO carrierOnce daily · 4–6 weeksApplied to the skin in a DMSO solution to help absorption; used in practice as a non-oral option [4].

Noopept (Omberacetam)

Oral

  • 10 mg twice daily (20 mg/day)Twice daily (morning and afternoon) · 56 days (8 weeks) per clinical studyDose used in a controlled human study of mild cognitive impairment, improving cognition with good tolerability [6].

Applications

Best suited for

Dihexa

Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, [6] making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. [6] This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models [4][6] positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.

Noopept (Omberacetam)

Cognitive enhancement for learning, memory formation, and information retrieval
Noopept (Omberacetam) is particularly well-suited for individuals focused on cognitive enhancement for learning, memory formation, and information retrieval. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection against oxidative stress and age-related cognitive decline
Noopept (Omberacetam) is particularly well-suited for individuals focused on neuroprotection against oxidative stress and age-related cognitive decline. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms
Noopept (Omberacetam) is particularly well-suited for individuals focused on nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Support during periods of intense intellectual work or study
Noopept (Omberacetam) is particularly well-suited for individuals focused on support during periods of intense intellectual work or study. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Dihexa

Common

  • Headache
  • Vivid dreams or altered sleep patterns
  • Emotional sensitivity
  • Mild fatigue during adjustment

Uncommon

  • Gastrointestinal discomfort

Serious

  • Theoretical oncogenic risk from c-Met activation

Noopept (Omberacetam)

Common

  • Headache
  • Irritability or restlessness
  • Sleep disturbance
  • Mild gastrointestinal discomfort
  • Vivid dreams

Uncommon

  • Blood pressure increase

Serious

  • Allergic reaction

Research status

Safety & evidence

Dihexa

Evidence level
Preclinical only — animal and cell-culture studies; no human trials
FDA status
Research compound
Safety overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. [7] The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. [7] The extremely long half-life (~12 days) [6][7] raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.

Contraindications

  • Known or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
  • Pregnancy and breastfeeding — no safety data available
  • History of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
  • Severe hepatic impairment

Noopept (Omberacetam)

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Noopept demonstrates excellent safety in Russian clinical trials with LD50 >2000 mg/kg (oral, rats)—approximately 100 times higher than therapeutic doses. No serious adverse events reported in human studies up to 30 mg/day for 6-12 weeks. Mild side effects (headache, irritability) occur in <5% of users and resolve with dose reduction. No carcinogenicity, mutagenicity, or teratogenicity in preclinical testing; minimal drug interactions due to lack of hepatic CYP450 metabolism.

Contraindications

  • Known hypersensitivity to Noopept, piracetam, or other racetam-class compounds
  • Pregnancy and breastfeeding — insufficient safety data
  • Severe hepatic impairment — Noopept undergoes hepatic metabolism
  • Severe renal impairment — metabolites are renally excreted
  • Lactose intolerance (some tablet formulations contain lactose as excipient)

Decision guide

Which is right for you?

Dihexa

Choose Dihexa if…

  • Cognitive enhancement and memory consolidation in age-related decline
  • Supporting neuroplasticity and new synaptic connection formation
  • Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
  • Nootropic stacking for individuals seeking enhanced learning capacity

Noopept (Omberacetam)

Choose Noopept (Omberacetam) if…

  • Cognitive enhancement for learning, memory formation, and information retrieval
  • Neuroprotection against oxidative stress and age-related cognitive decline
  • Nootropic stacking — complements racetams, cholinergics, and neurotrophic peptides through distinct mechanisms
  • Support during periods of intense intellectual work or study